Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma
Soft tissue sarcomas, depending on the subtype and grade, frequently recur and become metastatic after localized treatment. There is now great interest in applying immunotherapy to sarcomas to immuno-profile the different subtypes and immune monitor for prognosis. Our group previously showed that key immunotherapy target genes are present in sarcomas. Here, we extend our findings by demonstrating that sarcomas with a relatively high mutational load are likely to be more sensitive to immunotherapy compared to sarcomas with a lower mutation load. We also show that sarcomas with a higher mutation load are associated with the expression of key immune-related genes. We found that CD8+ T cells are present in sarcoma subtypes and that PD-L2 is highly expressed. These findings further define potential mechanisms behind the immunotherapy response of specific sarcoma subtypes and can be used to develop more optimal treatments in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancers - 13(2021), 20 vom: 19. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Roszik, Jason [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immune checkpoint |
|---|
| Anmerkungen: |
Date Revised 26.10.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers13205249 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33220538X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33220538X | ||
| 003 | DE-627 | ||
| 005 | 20231225215120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13205249 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1107.xml |
| 035 | |a (DE-627)NLM33220538X | ||
| 035 | |a (NLM)34680396 | ||
| 035 | |a (PII)5249 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Roszik, Jason |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.10.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Soft tissue sarcomas, depending on the subtype and grade, frequently recur and become metastatic after localized treatment. There is now great interest in applying immunotherapy to sarcomas to immuno-profile the different subtypes and immune monitor for prognosis. Our group previously showed that key immunotherapy target genes are present in sarcomas. Here, we extend our findings by demonstrating that sarcomas with a relatively high mutational load are likely to be more sensitive to immunotherapy compared to sarcomas with a lower mutation load. We also show that sarcomas with a higher mutation load are associated with the expression of key immune-related genes. We found that CD8+ T cells are present in sarcoma subtypes and that PD-L2 is highly expressed. These findings further define potential mechanisms behind the immunotherapy response of specific sarcoma subtypes and can be used to develop more optimal treatments in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a TCGA | |
| 650 | 4 | |a immune checkpoint | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a mutational burden | |
| 650 | 4 | |a next-generation sequencing | |
| 650 | 4 | |a soft tissue sarcoma | |
| 700 | 1 | |a Mustachio, Lisa Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Livingston, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Groisberg, Roman |e verfasserin |4 aut | |
| 700 | 1 | |a Carmagnani Pestana, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e verfasserin |4 aut | |
| 700 | 1 | |a Conley, Anthony P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 13(2021), 20 vom: 19. Okt. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:20 |g day:19 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers13205249 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 20 |b 19 |c 10 | ||